Argenx
ARGX
#435
Rank
A$83.00 B
Marketcap
A$1,328
Share price
0.37%
Change (1 day)
58.49%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): A$23.66

According to Argenx 's latest financial reports the company's current EPS (TTM) is A$22.93. In 2025 the company made an earnings per share (EPS) of A$30.57 an increase over its 2024 EPS that were of A$20.19.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$23.66-22.59%
2025A$30.5751.44%
2024A$20.19-369.77%
2023A-$7.48-60.46%
2022A-$18.9363.33%
2021A-$11.59-40.37%
2020A-$19.43183.47%
2019A-$6.86123.09%
2018A-$3.0754.93%
2017A-$1.9814.07%
2016A-$1.7413.05%
2015A-$1.54-36.34%
2014A-$2.42209.04%
2013A-$0.78-33.99%
2012A-$1.18185.59%
2011A-$0.41